EXAS - Exact Sciences Corp Stock Price, Fair Value and News

58.79USD-4.45 (-7.04%)Market Closed

Market Summary

USD58.79-4.45

Market Closed

-7.04%

EXAS Alerts

1 major insider sales recently.

EXAS Stock Price

View Fullscreen

EXAS RSI Chart

EXAS Valuation

Market Cap

11.5B

Price/Earnings (Trailing)

-56.23

Price/Sales (Trailing)

4.59

EV/EBITDA

-59.65

Price/Free Cashflow

359.55

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

73.83%

EBT Margin

-8.07%

Return on Equity

-6.49%

Return on Assets

-3.15%

Free Cashflow Yield

0.28%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

16.98%

Rev. Growth (Qtr)

2.95%

EXAS Earnings

Earnings (TTM)

-204.1M

Earnings Growth (Yr)

61.04%

Earnings Growth (Qtr)

-6.4K%

Breaking Down EXAS Revenue

Last 7 days

0.0%

Last 30 days

-0.8%

Last 90 days

-1.6%

Trailing 12 Months

-0.5%

How does EXAS drawdown profile look like?

EXAS Financial Health

Current Ratio

2.32

Debt/Equity

0.49

Debt/Cashflow

0.1

EXAS Investor Care

Shares Dilution (1Y)

1.86%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.2B	2.3B	2.4B	2.5B
2022	1.9B	1.9B	2.0B	2.1B
2021	1.5B	1.7B	1.8B	1.8B
2020	1.1B	1.1B	1.3B	1.5B
2019	526.2M	623.2M	723.7M	876.3M
2018	307.9M	353.2M	398.9M	454.5M
2017	132.9M	169.4M	213.8M	266.0M
2016	50.0M	63.1M	78.6M	99.4M
2015	5.8M	13.9M	26.5M	39.4M
2014	3.4M	2.4M	1.3M	1.8M
2013	4.1M	4.1M	4.1M	4.1M
2012	4.2M	4.2M	4.2M	4.1M
2011	5.1M	4.8M	4.5M	4.2M
2010	0	5.0M	5.1M	5.3M
2009	0	0	0	4.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exact Sciences Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	baranick brian	sold	-73,393	79.43	-924	evp, gm., precision oncology
Apr 01, 2024	condella sarah	sold	-140,000	70.00	-2,000	evp, human resources
Mar 28, 2024	condella sarah	sold	-140,000	70.00	-2,000	evp, human resources
Mar 01, 2024	elliott jeffrey thomas	sold	-143,080	59.32	-2,412	chief financial officer
Mar 01, 2024	cunningham everett	sold	-143,080	59.32	-2,412	chief commercial officer
Mar 01, 2024	condella sarah	sold	-102,268	59.32	-1,724	evp, human resources
Mar 01, 2024	herriott james	sold	-51,133	59.32	-862	general counsel
Mar 01, 2024	conroy kevin t	sold	-490,636	59.32	-8,271	president and ceo
Mar 01, 2024	levangie daniel j	sold	-287,500	57.5	-5,000	-
Mar 01, 2024	orville jacob a	sold	-127,775	59.32	-2,154	general manager, screening

Which funds bought or sold EXAS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	-246	3,453	-%
Apr 24, 2024	PSI Advisors, LLC	unchanged	-	-246	3,453	-%
Apr 24, 2024	Activest Wealth Management	unchanged	-	-281	3,936	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	reduced	-0.4	-151,000	1,988,000	0.01%
Apr 24, 2024	IMA Wealth, Inc.	reduced	-3.3	-241,151	2,237,480	1.06%
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-13.29	-123,780	525,616	-%
Apr 24, 2024	McCarthy Grittinger Financial Group, LLC	unchanged	-	-2,730	38,329	0.01%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	reduced	-13.48	-1,853,580	7,782,090	0.02%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-2,706	37,983	0.02%
Apr 24, 2024	Krilogy Financial LLC	added	37.5	410,596	1,858,680	0.14%

Are Funds Buying or Selling EXAS?

Are funds buying EXAS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EXAS

No. of Funds

EXAS Alerts

1 major insider sales recently.

Unveiling Exact Sciences Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.71%	17,559,751	SC 13G/A
Feb 09, 2024	wellington management group llp	5.83%	10,536,759	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	11,103,191	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	9.5%	17,342,002	SC 13G/A
Oct 10, 2023	jpmorgan chase & co	10.3%	18,652,296	SC 13G
Feb 10, 2023	ark investment management llc	9.03%	16,040,490	SC 13G/A
Feb 09, 2023	vanguard group inc	9.71%	17,252,465	SC 13G/A
Feb 07, 2023	blackrock inc.	6.4%	11,354,134	SC 13G/A
Feb 06, 2023	wellington management group llp	5.86%	10,404,476	SC 13G/A
Sep 12, 2022	price t rowe associates inc /md/	3.7%	6,464,337	SC 13G/A

Recent SEC filings of Exact Sciences Corp

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Exact Sciences Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	1.02%	7.91%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.67%	2.31%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.56%	5.45%	32.59	5.98	-2.81%	-6.58%
DGX	14.3B	9.3B	6.43%	-6.08%	16.85	1.54	-3.29%	6.68%
CRL	12.3B	4.1B	-9.86%	27.62%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-1.17%	90.89%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	-0.82%	-0.49%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	0.12%	80.51%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-18.50%	-26.31%	1.7K	2.88	28.93%	111.61%
GH	2.2B	563.9M	5.66%	-15.62%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	413.2M	280.3M	-17.90%	-0.25%	-2.17	1.47	-12.89%	-148.37%
ACRS	83.0M	31.2M	0.86%	-86.93%	-0.94	2.66	5.03%	-1.81%
APDN	81.2M	9.0M	-50.00%	-75.76%	-11.23	9.02	-53.31%	2.21%
AWH	42.0M	9.2M	-4.49%	-35.24%	-2.51	4.58	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Exact Sciences Corp News

Latest updates

Exact Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.0%	646,885,000	628,338,000	622,093,000	602,450,000	552,995,000	523,073,000	521,640,000	486,571,000	473,812,000	456,379,000	434,819,000	402,077,000	466,339,000	408,363,000	268,868,000	347,821,000	295,575,000	218,805,000	199,870,000	162,043,000	142,981,000
Cost Of Revenue	2.0%	171,865,000	168,526,000	156,991,000	156,866,000	147,152,000	147,937,000	144,600,000	134,705,000	119,058,000	115,738,000	113,968,000	109,993,000	99,765,000	95,061,000	77,892,000	81,606,000	70,416,000	52,335,000	51,139,000	42,827,000	37,827,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166,046,000	148,307,000	118,791,000	104,821,000
Costs and Expenses	4.0%	721,126,000	693,516,000	699,022,000	679,541,000	671,877,000	647,887,000	681,224,000	663,558,000	695,262,000	618,402,000	606,483,000	702,618,000	881,318,000	611,698,000	359,542,000	430,194,000	391,655,000	254,531,000	233,772,000	230,117,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	201,706,000	182,127,000	186,985,000	154,137,000
S&GA Expenses	10.0%	190,477,000	173,159,000	176,490,000	186,964,000	210,211,000	187,697,000	215,922,000	232,181,000	284,304,000	196,617,000	194,827,000	186,141,000	166,827,000	136,481,000	118,862,000	167,749,000	119,851,000	86,196,000	88,190,000	90,939,000	76,773,000
R&D Expenses	3.1%	114,922,000	111,446,000	104,095,000	95,419,000	94,274,000	90,813,000	106,083,000	102,248,000	88,488,000	75,356,000	106,235,000	115,567,000	446,447,000	31,471,000	32,673,000	43,509,000	43,223,000	34,714,000	29,972,000	31,785,000	20,700,000
EBITDA Margin	-16.6%	-0.07	-0.06	-0.17	-0.22	-0.29	-0.35	-0.37	-0.39	-0.46	-0.52	-0.55	-0.54	-	-	-	-	-	-	-	-	-
Interest Expenses	494.2%	31,029,000	-7,871,000	-7,818,000	4,107,000	33,858,000	-5,235,000	-4,511,000	-4,478,000	32,554,000	-4,680,000	-4,652,000	-4,616,000	131,323,000	-4,478,000	-4,300,000	-54,604,000	-13,688,000	-13,209,000	-12,712,000	-21,990,000	-10,972,000
Income Taxes	-400.2%	-600,500	200,000	1,107,000	1,700,000	-2,189,500	-3,116,000	-1,751,000	-2,000,000	-4,243,000	-3,900,000	4,000,000	-242,800,000	-164,000	-2,752,000	-305,000	-2,237,000	-184,628,000	683,000	-443,000	-470,000	7,000
Earnings Before Taxes	-4929.9%	-50,376,000	1,043,000	-79,919,000	-72,494,000	-129,927,000	-151,877,000	-167,814,000	-182,952,000	-224,854,000	-170,796,000	-172,887,000	-273,969,000	-418,496,000	-205,290,000	-68,397,000	-136,880,000	-106,683,000	-39,842,000	-38,945,000	-83,409,000	-53,967,000
EBT Margin	31.0%	-0.08	-0.12	-0.19	-0.24	-0.30	-0.36	-0.39	-0.41	-0.48	-0.59	-0.63	-0.63	-	-	-	-	-	-	-	-	-
Net Income	-6367.8%	-49,766,000	794,000	-81,026,000	-74,151,000	-127,745,000	-148,761,000	-166,063,000	-180,937,000	-220,611,000	-166,938,000	-176,912,000	-31,164,000	-418,332,000	-202,538,000	-68,092,000	-134,643,000	77,973,000	-40,525,000	-38,502,000	-82,939,000	-53,974,000
Net Income Margin	30.4%	-0.08	-0.12	-0.19	-0.23	-0.30	-0.36	-0.38	-0.40	-0.34	-0.45	-0.48	-0.47	-	-	-	-	-	-	-	-	-
Free Cashflow	4292.1%	34,627,000	-826,000	65,703,000	-67,575,000	-20,839,000	-85,563,000	-124,242,000	-207,377,000	-83,964,000	-79,644,000	15,753,000	-90,147,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.8%	6,471	6,421	6,356	6,304	6,227	6,307	6,437	6,491	6,685	6,654	6,724	6,735	4,925	4,354	4,468	4,461	3,506	1,759	1,782	1,771	1,524
Current Assets	4.0%	1,194	1,148	1,174	1,091	982	1,049	1,102	1,215	1,426	1,616	1,669	1,775	2,199	1,607	1,505	1,484	554	1,320	1,375	1,407	1,228
Cash Equivalents	1.8%	605	595	604	421	242	235	213	190	315	274	364	1,104	1,492	807	704	701	178	1,034	205	285	160
Inventory	-4.0%	127	133	131	124	118	115	115	113	105	95.00	90.00	89.00	92.00	80.00	82.00	69.00	62.00	54.00	48.00	44.00	39.00
Net PPE	-	698	-	-	-	685	-	-	623	580	524	502	483	452	456	463	465	455	371	335	292	245
Goodwill	0.0%	2,367	2,367	2,346	2,346	2,346	2,345	2,346	2,335	2,335	2,243	2,243	57.00	1,238	1,238	1,238	30.00	1,203	-	-	-	15.00
Liabilities	0.8%	3,326	3,300	3,299	3,247	3,184	3,198	3,228	3,232	3,297	3,197	3,165	3,086	2,690	2,017	1,957	1,923	1,218	1,011	1,016	994	843
Current Liabilities	8.0%	515	477	488	367	413	424	443	481	517	710	676	629	633	253	222	244	236	481	492	168	136
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,555	1,534	1,514	804	477	470	25.00	24.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	316	312	0.00	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,555	1,534	1,514	804	477	470	25.00	24.00
Shareholder's Equity	0.8%	3,145	3,121	3,057	3,058	3,043	3,109	3,209	3,258	3,388	3,458	3,559	3,649	2,236	1,731	1,887	1,896	1,958	748	766	777	447
Retained Earnings	-1.5%	-3,469	-3,419	-3,420	-3,339	-3,265	-3,137	-2,988	-2,822	-2,641	-2,420	-2,253	-2,077	-2,045	-1,531	-1,311	-1,225	-1,119	-1,197	-1,157	-1,118	-1,035
Additional Paid-In Capital	1.1%	6,611	6,540	6,476	6,397	6,312	6,255	6,205	6,086	6,029	5,877	5,811	5,724	4,279	3,866	3,820	3,763	3,406	1,945	1,920	1,894	1,717
Shares Outstanding	0.3%	181	181	181	180	178	176	176	174	171	172	170	169	-	-	-	-	-	-	-	-	-
Float	-	-	-	16,796	-	-	-	6,905	-	-	-	21,212	-	-	-	12,901	-	-	-	15,070	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	185.5%	70.00	24.00	100	-38.22	52.00	-40.93	-60.92	-173	-24.57	-40.77	40.00	-77.23	111	82.00	-6.87	-49.83	-25.30	-29.15	17.00	-74.15	-0.85
Share Based Compensation	-5.3%	59.00	62.00	62.00	49.00	46.00	50.00	59.00	52.00	113	5.00	1.00	77.00	42.00	41.00	40.00	30.00	48.00	24.00	20.00	16.00	16.00
Cashflow From Investing	-102.5%	-66.77	-32.97	66.00	83.00	-58.16	65.00	22.00	46.00	78.00	-49.24	-793	-317	-306	17.00	-6.38	-405	-838	857	-102	-41.20	-9.80
Cashflow From Financing	10809.8%	10.00	0.00	16.00	134	10.00	0.00	63.00	3.00	-12.20	0.00	13.00	7.00	880	4.00	16.00	979	7.00	1.00	5.00	240	9.00

EXAS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 2,499,766	$ 2,084,279	$ 1,767,087
Operating expenses:
Cost of sales (exclusive of amortization of acquired intangible assets)	654,248	574,394	458,757
Research and development	425,882	393,418	385,646
Sales and marketing	727,090	846,011	861,889
General and administrative	893,204	737,304	801,262
Amortization of acquired intangible assets	92,160	97,450	95,001
Impairment of long-lived assets	621	15,969	20,210
Total operating expenses	2,793,205	2,664,546	2,622,765
Other operating income (loss)	78,427	(13,244)	0
Loss from operations	(215,012)	(593,511)	(855,678)
Other income (expense)
Investment income (loss), net	32,713	(19,425)	31,778
Interest expense	(19,447)	(19,634)	(18,606)
Total other income (expense)	13,266	(39,059)	13,172
Net loss before tax	(201,746)	(632,570)	(842,506)
Income tax benefit (expense)	(2,403)	9,064	246,881
Net loss	$ (204,149)	$ (623,506)	$ (595,625)
Net loss per share - basic (in dollars per share)	$ (1.13)	$ (3.54)	$ (3.48)
Net loss per share - diluted (in dollars per share)	$ (1.13)	$ (3.54)	$ (3.48)
Weighted average common shares outstanding - basic (in shares)	180,144	176,351	171,348
Weighted average common shares outstanding - diluted (in shares)	180,144	176,351	171,348

EXAS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 605,378	$ 242,493
Marketable securities	172,266	389,564
Accounts receivable, net	203,623	158,043
Inventory	127,475	118,259
Prepaid expenses and other current assets	85,627	73,898
Total current assets	1,194,369	982,257
Long-term assets:
Property, plant and equipment, net	698,354	684,756
Operating lease right-of-use assets	143,708	167,003
Goodwill	2,367,120	2,346,040
Intangible assets, net	1,890,396	1,956,240
Other long-term assets, net	177,387	90,577
Total assets	6,471,334	6,226,873
Current liabilities:
Accounts payable	78,816	74,916
Accrued liabilities	341,683	299,216
Operating lease liabilities, current portion	29,379	28,366
Other current liabilities	14,823	10,249
Total current liabilities	514,701	412,747
Convertible notes, net	2,314,276	2,186,106
Long-term debt, less current portion	0	50,000
Other long-term liabilities	335,982	352,459
Operating lease liabilities, less current portion	161,070	182,399
Total liabilities	3,326,029	3,183,711
3326029000
Stockholders’ equity:
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—181,364,180 and 177,925,631 shares at December 31, 2023 and December 31, 2022	1,815	1,780
Additional paid-in capital	6,611,237	6,311,644
Accumulated other comprehensive income (loss)	1,428	(5,236)
Accumulated deficit	(3,469,175)	(3,265,026)
Total stockholders’ equity	3,145,305	3,043,162
Total liabilities and stockholders’ equity	6,471,334	6,226,873
Loans Payable, Current	$ 50,000	$ 0

About Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

CEO	Mr. Kevin T. Conroy
WEBSITE	exactsciences.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	6300

Exact Sciences Corp Frequently Asked Questions

What is the ticker symbol for Exact Sciences Corp? What does EXAS stand for in stocks?

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exact Sciences Corp (EXAS)?

As of Wed Apr 24 2024, market cap of Exact Sciences Corp is 11.48 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers. The fair value of Exact Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exact Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXAS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exact Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

What is Exact Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, EXAS's PE ratio (Price to Earnings) is -56.23 and Price to Sales (PS) ratio is 4.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exact Sciences Corp's stock?

In the past 10 years, Exact Sciences Corp has provided 0.175 (multiply by 100 for percentage) rate of return.